News FDA warns of genital gangrene risk with diabetes drug class The US regulator released an official risk warning of a rare genital infection identified in 12 patients, including one fatality, after using SGLT2 class drugs for type 2 diabetes.
Views & Analysis SGLT2 inhibitors: an emerging option for cardiologists? With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists are still cautious.
UK & Europe AZ’s diabetes combination Qtern approved in Europe The European Commission has granted marketing approval to a new combination pill from AstraZeneca to treat type 2 diabetes.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
